All In Biotech

Drug Trial Radar · NCT03316222

Study of GNS561 in Patients With Liver Cancer

Phase 1/2a Study to Evaluate the Safety, Activity, and Pharmacokinetics of Escalating Doses of GNS561 in Patients With Primary and Secondary Liver Cancer

Last checked: Nov 19, 2026Latest source record: May 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

50

Actual

Start

Apr 4, 2018

Primary completion

Jan 15, 2021

Study completion Apr 25, 2022

Sponsor

Lead sponsor
Genoscience PharmaIndustry
Sponsor type
Industry
First posted
Oct 20, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first in human, open-label dose escalation study to investigate the safety, tolerability and pharmacokinetics of GNS561 in patients Primary and Secondary liver cancer

Conditions

  • Hepatocellular Carcinoma
  • Cholangiocarcinoma, Intrahepatic

Interventions

  • GNS561Drug

    Escalating doses to be administered 3 times a week.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Limiting ToxicityTime frame: Dose-Limiting Toxicity will be evaluated during the 4 - week dose escalation phase.

Locations

5 sites in 3 countries. Site status is shown where the registry gives one.

  • Memorial Sloan Kettering

    New York, New York

  • Jules Bordet Institute

    Brussels, Belgium

  • CHU Grenoble

    Grenoble, France

  • Croix-Rousse Hospital

    Lyon, France

  • Saint-Joseph Hospital

    Paris, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.